Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump

Drugmakers aim to step up production by 15-20% in the near term

Anti-rabies vaccine (ARV) and immunoglobulin sales are gradually recovering after the Covid-19 slump, amid a marked increase in dog bite incidence. 

The rise in sales follows a 76 per cent increase in dog bites, from 2.1 million in 2022 to 3.7 million in 2024. As a result, vaccine makers are preparing to ratchet up production. 

Bharat Serums and Vaccines (BSV), an arm of Mankind Pharma, told Business Standard that it aims to expand manufacturing by 15-20 per cent, supporting India’s mission to eliminate rabies through timely and complete after-exposure treatment. 

Data from market research firm Pharmarack shows that the combined